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Abstract
Background: Environmental and physiological conditions make older adults more likely to lose synchronization to
their local time and experience sleep disturbances. A regular, 24-hour light/dark cycle promotes synchronization. It
is now well established that the circadian system is maximally sensitive to short-wavelength (blue) light. The
purpose of the present study was to measure dose effectiveness (amounts and durations) of short-wavelength
(blue) light for stimulating the circadian systems of older adults. We investigated the impact of six corneal
irradiances (0.7 to 72 μW/cm
2) of 470-nm light on nocturnal melatonin production. Nine participants, each over 50
years of age completed a within-subjects study. Each week, participants were exposed to one of the six irradiances
of 470-nm light for 90 minutes.
Findings: A two-factor (6 corneal irradiances × 10 exposure durations), within-subjects analysis of variance
(ANOVA) was conducted using the melatonin suppression levels. The ANOVA revealed a significant main effect of
corneal irradiance (F5, 30 = 9.131, p < 0.0001), a significant main effect of exposure duration (F9, 54 = 5.731, p <
0.0001), and a significant interaction between these two variables (F45,270 = 1.927, p < 0.001). Post hoc t-tests
revealed that corneal irradiances as low as 2 μW/cm
2 reliably suppressed melatonin after 90-minute exposure
whereas 0.7 μW/cm
2 did not.
Conclusions: Sleep disorders are common and a serious problem for millions of older adults. The present results
showed that comfortable, precise and effective doses of light can be prescribed to older adults to reliably stimulate
the circadian system that presumably would promote entrainment and, thus, regular sleep. Field studies on the
impact of short-wavelength-light doses on sleep efficiency in older adults should be performed.
Introduction
A large and growing body of research shows that a regu-
lar, 24-hour light/dark cycle synchronizes circadian
rhythms in all species, including humans, to local time
on earth. Light levels required to activate the circadian
system are higher than those required for vision [1].
Since older adults are less active and tend to stay indoors
more often where light levels tend to be low, they may
not be exposed to lighting that sufficiently stimulates
their circadian system [2]. Moreover, these same older
adults commonly have less light reaching their retina due
to natural age-related reductions in pupil size (senile
miosis) and in crystalline lens transmission [3]. Together,
these environmental and physiological conditions make
older adults more likely to lose entrainment to their local
time and, as a result, more likely to experience sleep dis-
turbances [2,4,5].
Timed light treatments have been shown to improve
circadian entrainment in older persons, including those
with Alzheimer’s disease (AD), a population that is per-
haps most susceptible to circadian disruption through
light restriction [6]. Clinical research has shown, for exam-
ple, that exposing persons with AD to light levels higher
than what they would normally experience in their homes
or in institutions during the day and darkness at night can
consolidate their rest/activity patterns [7,8]. Morning and
evening bright light exposures (> 2,500 lux at the cornea)
have been shown to improve nighttime sleep, increase
daytime wakefulness, reduce evening agitation behavior,
and consolidate rest/activity patterns of persons with AD
[8-11]. Riemersma-van der Lek and colleagues demon-
strated that all-day exposure to high levels of a white light
(i.e., at least 1000 lux at the eye of a 4100 K light source)
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any medium, provided the original work is properly cited.improved sleep efficiency and cognition in patients with
AD as well as reduced symptoms of depression [12]. Light
applied in the evening has also been shown to be effective
in phase delaying the circadian system of older people
without dementia, allowing them to fall asleep later and
wake up later [13].
Although bright light interventions appear to be effec-
tive for promoting circadian entrainment and improving
sleep efficiency, they can be expensive, time consuming
for caregivers, and uncomfortable for older adults, who
show symptoms of photophobia. In fact, there is evidence
that light treatment may not always result in better sleep
in older adults. Light treatment alone (1 hour of 2,500
lux at the angle of gaze) did not improve nighttime sleep,
daytime wake and rest activity in AD patients [14,15].
These negative results may reflect problems with compli-
a n c e ,s ot h e r ei san e e dt od e v e l o pm o r ep r a c t i c a la n d ,
thus, more effective methods for light delivery.
Treatment efficacy (i.e., effectiveness per electrical watt)
is also important to consider for practical applications.
One simple method for improving treatment efficacy is
placing the light source closer to the eyes. The irradiance
at the cornea falls off with the square of the distance from
the source, so small reductions in this distance have dis-
proportionately large increases in light exposure to the
retina. Tuning the light spectrum for maximum effect also
increases treatment efficacy. Research has demonstrated
that the spectral sensitivity of the circadian system differs
from the spectral sensitivity of the achromatic visual chan-
nel, which is used for such visual activities as reading.
Short-wavelength (blue) light between approximately
440 nm and 470 nm is maximally effective at stimulating
the human circadian system, as measured through acute
melatonin suppression and phase shifting of the melatonin
rhythm [16-18].
One way to provide older adults with inexpensive, low-
powered light sources that provide sufficient levels of cir-
cadian-effective light would be to mount short-wavelength
light-emitting diodes (LEDs) on spectacle frames. With a
thoughtful design, the intensity distribution of the circa-
dian-effective light sources should not interfere with the
performance of visual tasks. Some engineering sophistica-
tion is also needed to precisely control the timing and
duration of the light dose. Temporally controlled 470-nm
(blue) LEDs mounted on spectacle frames would be inex-
pensive, require little, if any, maintenance, and would be
comfortable and safe for users as long as the dose was
properly prescribed. A prototype of the device was devel-
oped and its effectiveness at two irradiances was measured
previously by Figueiro et al [19].
The purpose of the present study was to extend the
findings from Figueiro et al [19] to more precisely mea-
sure dose effectiveness (amounts and durations) of short-
wavelength (blue) light for stimulating the circadian
systems of older adults. A self-powered, blue-light goggle
system had been developed for the previous study and
was used again here to deliver the light doses. Nocturnal
melatonin suppression was used as the measure of the
threshold for light activation and of dose efficacy. In
addition, these data would be expected to be used to
refine the mathematical model of human circadian
phototransduction [17] to predict circadian effectiveness
for other light sources. Once the dose effectiveness for
short-wavelength stimulus is known, the dose effective-
ness for other narrowband sources can be estimated
from the modeled spectral sensitivity function.
Methods
The prototype blue-light goggles were developed under a
grant from the National Institutes on Aging to deliver cir-
cadian-effective light doses to adults 50 years of age and
older. Previously, nocturnal melatonin suppression was
measured at just two light doses from these blue-light gog-
gles [19]. The present study was designed to extend those
findings by measuring the effectiveness of additional doses
from these goggles for suppressing nocturnal melatonin in
older adults. The Institute Review Board (IRB) of Rensse-
laer Polytechnic Institute approved the present experimen-
tal protocol and all subjects were asked to sign a written
informed consent form.
Subjects
Of the eleven subjects who completed the previous
study [19], nine were still available for further study;
therefore only data for the nine subjects who completed
all experimental conditions are included here. These
subjects had been previously recruited through e-mail
notices, posters, and word-of-mouth. Eligibility for the
study required subjects to be over the age of 50 years
a n dt ob ef r e eo fa n ym a j o rh e a l t hp r o b l e m s ,s u c ha s
cardiovascular disease, diabetes, or high blood pressure.
Potential subjects were excluded if they were taking
over-the-counter melatonin or prescription medication
such as blood pressure medicine, antidepressants, sleep
medicine, hormone replacement therapy or beta-block-
ers. Potential subjects who stated they had any eye dis-
ease (such as cataract, glaucoma and color blindness)
were not accepted into the study. Seven of nine subjects
completed the Munich ChronoType questionnaire
(MCTQ) [20]. Because the experiment would be con-
ducted in the early part of the night, extreme late
chronotypes were excluded to assure melatonin levels
would be high at the time of the experiment; of the
seven subjects who completed the MCTQ, all were
moderate to early chronotypes with a mean ± standard
deviation of 1.3 ± 1.0. All subjects contributing to the
present results were between 51 and 62 years of age
(mean ± standard deviation, 56.2 ± 3.9 years).
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Subjects who completed the 2-night protocol reported by
Figueiro et al [19] took part in the additional five-night
protocol; the sessions took place on Friday nights
(between September 2009 and April 2010) and were
scheduled at least one week apart. On the weeks of the
experimental sessions, subjects were instructed to go to
bed between 21:00 and 23:00. On the day of the experi-
ment, subjects were asked to refrain from caffeine and
alcohol 12 hours prior to the start of the experiment and
to arrive at the lab at 22:00. Upon arrival, a registered
nurse inserted an indwelling catheter into an arm of each
subject. At 23:00, room lights were turned off, except for
two red LED traffic signal lights (lmax = 640 nm) placed
on the floor, outside the subjects’ field of view. These
traffic signals provided indirect illumination in the space,
less than 1 lux at the cornea, that was sufficient for peo-
ple to safely navigate in the space without stimulating
their circadian systems.
After the room lights were turned off, the subjects were
seated and watched a movie that was projected on a
screen about 20 feet (6 meters) away. The measured (poly-
chromatic) illuminance at the subjects’ cornea reflected
from the projection screen alone ranged from 0.14 to
0.2 lux; this level is too low to stimulate the circadian sys-
tem [21]. The movie kept subjects awake, minimizing the
likelihood of eye closures. Moreover, experimenters con-
tinuously monitored the subjects to ensure that they had
their eyes open. Subjects were not allowed to drink or eat
after 23:30.
Table 1 shows the times that blood and saliva samples
were taken from the first subject in a session. To allow
the nurse to collect the blood samples from every subject
in a session, data collection times for the other subjects
were each staggered by about 2 minutes. The first two
blood and saliva samples were collected at the same time
(23:50 and 00:00). Immediately after the second sample
was collected from the subjects, they were asked to put
on the blue-light goggles (described below), which
remained on for the remainder of the experimental
session.
One saliva and three blood samples were collected
from each subject at each of seven appointed times in a
90-minute session. Saliva samples were obtained using
the Salivette system (ALPCO Diagnostics, Salem, NH,
U S A ) .T h r e e ,3 - m lb l o o ds a m p l e sw e r ed r a w nb yt h e
nurse at each of the prescribed times; the first sample
was always discarded and the second and third samples
were spun in a centrifuge for 15 minutes. Frozen saliva
and plasma samples were subsequently sent to an inde-
pendent laboratory (Pharmasan Labs, Osceola, WI) for
melatonin radioimmunoassay. The sensitivity of the sal-
iva assay was 0.7 pg/ml and the intra- and inter-assay
coefficients of variability (CVs) were 12.1% and 13.2%,
respectively. The sensitivity of the plasma assay was
3.5 pg/ml and the intra- and inter-assay CVs were 8.1%
and 14.8%, respectively.
All subjects saw all lighting conditions described in
Table 2 in a counterbalanced order within a set of ses-
sions. Thus, different light exposures were provided to
subjects on any given night. When experiencing the dark
(control) condition, subjects wore non-energized blue-
light goggles. Melatonin concentrations in saliva and in
plasma were assayed at different times as three different
batches, also shown in Table 2.
At completion of pupil measurements (described
below), room lighting was turned on and the registered
nurse removed the indwelling catheter from the sub-
jects’ arms and subjects were offered a ride home.
Light Levels
Topbulb.com produced the blue-light goggles used to deli-
ver the prescribed doses of light from LUXEON Rebel
(LXML - PB01) LEDs. Subjects wore the goggles while
they received one of seven irradiance levels at the cornea,
including the dark control condition without energizing
the LEDs. Table 2 shows the six average irradiance
(μW/cm
2) and illuminance (lux) levels, as well as the peak
and full width at half maximum (FWHM) wavelengths
generated by the energized goggles.
Four LEDs, two per goggle lens, with peak wavelengths
ranging from 466 to 474 nm were mounted to the top
inside rim of the goggles. The LEDS were located behind
at r a n s l u c e n tp l a s t i ct u b et od i f f u s et h el i g h ta n dt o
reduce point-source glare [22]. Although the amount of
light emitted by the LEDs was below levels that might be
of concern for blue light hazard [23], diffusing the light
sources further ensured safety. Heat from the LEDs was
dissipated via a heat sink strip. The LEDs were connected
by wire to a small control case (0.5 × 1.5 × 2.5 in. [1.3 ×
3.8 × 6.4 cm]), which held a 3.0 VDC two-battery power
source, and the control circuitry, including a Texas
Instruments voltage regulator (TPS77018DBVR 1.8 V).
The small control case also housed the LED driver
(Maxim Evaluation Kit -1848 EVKIT), which was used to
Table 1 Data collection times for the first subject in a session to provide blood and saliva samples
Dark Dark Goggles on Goggles on Goggles on Goggles on Goggles on
Blood 23:50 00:00 00:10 00:20 00:30 01:00 01:30
Saliva 23:50 00:00 00:05 00:15 00:25 00:45 01:15
Figueiro et al. BMC Research Notes 2011, 4:334
http://www.biomedcentral.com/1756-0500/4/334
Page 3 of 8adjust the flux emitted by the LEDs to the prescribed
light level in a session.
Prior to every session, new batteries were inserted into
the small control case. While the LED driver was
adjusted, light from the left and from the right goggle
lens LEDs were alternately measured with a Model 2300i
Action Research double monochrometer a Spectra Sense
Version 4.3.0 spectral radiometer using a 5 mm diameter
optical fiber ending in a lambertian diffuser as the sensor.
During measurements, the sensor was placed where the
subject’s corneas would be while wearing the goggles.
The average irradiance from the left and right lenses was
used to meet the prescribed light level.
After each session, while a subject continued to wear the
blue-light goggles at the session-prescribed corneal irradi-
ance, ten digital images of one eye of each subject were
acquired with a Sony video camera. To improve camera
image quality, an infrared (IR) source irradiated the eye.
Pupil size is unaffected by this supplemental source
because the retina is insensitive to IR radiation. Subjects
held a small ruler just below their eye during the image
capture as a reference, linear scale to estimate pupil dia-
meter. The captured image was printed and, using precise
calipers, the experimenter measured both the size of the
known ruler unit (e.g., 1 cm) and the size of the unknown
pupil diameter in the image. The ratio of the measured
ruler unit from the digital image to the known ruler unit
was then used to scale the measured pupil diameter from
the digital image to estimate the actual pupil diameter.
Three images were arbitrarily selected and used to esti-
mate the pupil diameter for a given subject. Thus, the
reported median pupil diameters in Table 2 are each
based upon the median of 27 pupil diameter estimates
(9 subjects × 3 samples). From the median pupil dia-
meters, pupil areas were calculated. Since there was no
evidence of anisocoria with any subject, the size of both
the left and right pupils should always be the same. Bino-
cular retinal light exposures were defined as the product
of the median corneal irradiance and the median pupil
area in units of deka-nanowatts (μW/cm
2 ×m m
2)o r
micro-lumens (lm/m
2 ×m m
2) where corneal illuminance
is considered.
Data Analyses
To more precisely determine the differential effects of light
exposure level and duration on melatonin concentrations
a series of normalizations were undertaken to minimize
systematic differences among the nine subjects, between
the two biomarker types (plasma and saliva), and among
assay batches (Table 2). This approach was the same as
that employed in the previous study by Figueiro and col-
leagues [19], except for the additional normalization for
assay batches. Although the assay methodology was not
changed, the absolute melatonin concentrations differed
systematically among the three batches sent for melatonin
assays as revealed by examination of the saliva and plasma
concentrations at 23:50 and 00:00, the two times, in the
dark, common to all experimental sessions. First, the raw
melatonin concentrations in a batch, either plasma or sal-
iva, were averaged, and the ratio of the batch average con-
centrations to the grand average concentrations were used
to normalize the different batches for plasma and saliva
concentrations. The same procedure was then followed to
normalize differences among subjects. Thus, any systema-
tic differences among batches, among subjects, and
between plasma and saliva melatonin concentrations were
minimized. The subject’s normalized melatonin concen-
trations, both plasma and saliva, for every exposure dura-
tion at a given retinal irradiance were then fitted with a
polynomial equation using a least squares criterion. Each
of those resulting normalized melatonin concentration
curves, one for every subject at every retinal irradiance,
including dark, were then adjusted to a common melato-
nin concentration value at 00:00; the adjustment was
based upon the reciprocal of the polynomial values at
00:00 for combined normalized plasma and saliva data.
Table 2 Lighting conditions presented to subjects
Batch Irradiance
(μW/cm
2)
Illuminance
(lux)
Peak wavelength
(nm)
FWHM
(nm)
Pupil diameter
(mm)
3 dark NA NA NA 5.5 (5.4 ± 0.51)
3 0.7 (0.7 ± 0.04) 0.61(.6 ± 0.16) 473 (473 ± 0.4) 18 (18 ± 0.83) 5.3 (5.2 ± 0.52)
3 2.0 (2 ± 0.08) 1.2 (1.5 ± 0.37) 462 (467 ± 5.5) 18 (18 ± 0.29) 4.9 (4.8 ± 0.53)
2 6.1 (6 ± 0.2) 5.8 (6.8 ± 3.1) 474 (474 ± 0.3) 20 (20 ± 0.3) 4.2 (4.4 ± 0.61)
1 11 (11 ± 2.6) 11 (11 ± 1.6) 474 (474 ± 1.8) 20 (20 ± 0.5) 3.8 (4.1 ± 0.91)
2 20 (20 ± 0.4) 12 (14 ± 4.1) 462 (466 ± 5.9) 19 (19 ± 1.1) 3.8 (4.1 ± 0.87)
1 72 (74 ± 7.3) 66 (60 ± 17) 473 (469 ± 6.3) 20 (20 ± 1.5) 3.4 (3.4 ± 0.33)
Medians and, in parentheses, means ± standard deviations of corneal irradiance, corneal illuminance, peak wavelength and full width at half maximum (FWHM)
wavelength delivered by the blue-light goggles used in the experiment. Peak wavelengths vary slightly because different goggles were used to deliver the
different light levels. Medians, means ± standard deviations of measured subject pupil diameter while wearing the blue-light goggles at the prescribed levels are
also provided. Pupil areas and corneal irradiances or corneal illuminance levels were used to estimate retinal light doses. Melatonin concentrations in saliva and
in plasma were assayed at different times as three different batches.
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calculated from the fitted melatonin concentration values
at each retinal irradiance and for all exposure durations;
the mean melatonin suppression (ms%) levels shown in
Figure 1 were based upon mean suppression levels from
every subject at each retinal irradiance and every exposure
duration. Suppression levels for a given subject were deter-
mined by the ratio of the melatonin concentrations after
exposure to a given retinal irradiance for a given duration
after 00:00 to the melatonin concentrations during the
dark night at the same clock time.
Results
Melatonin Suppression
Figure 1 shows mean nocturnal melatonin suppression
levels following exposure to each retinal irradiance level
at every exposure duration for both the plasma and the
saliva samples. A two-factor (6 corneal irradiances × 10
exposure durations), within-subjects analysis of variance
(ANOVA) was conducted using the melatonin suppres-
sion levels (SPSS version 13). The ANOVA revealed a
significant main effect of corneal irradiance (F5, 30 =
9.131, p < 0.0001), a significant main effect of exposure
duration (F9, 54 = 5.731, p < 0.0001), and a significant
interaction between these two variables (F45,270 =1 . 9 2 7 ,
p < 0.001). Table 3 shows the results of 60 post hoc, two-
tailed one sample t-tests to determine if the suppression
levels were significantly different than zero. Entries in the
table are the independent probabilities of a Type 1 error.
The Bonferonni-adjusted criterion probability of a Type
1 error is 0.0008; probabilities less than this criterion are
marked with asterisks in Table 3. The tendency for sig-
nificant post hoc comparisons to lie in the bottom right
corner of Table 3 illustrates the significant interaction
between exposure duration and corneal irradiance.
In order to estimate threshold values for melatonin
suppression by the 470-nm light, we compared the mela-
tonin concentrations in the dark to those after exposure
to 0.7 μW/cm
2 and 2 μW/cm
2. Figure 2 shows a plot of
the mean differences between the measured plasma mel-
atonin concentrations in the dark and those at both 0.7
μW/cm
2 and 2 μW/cm
2 at the same exposure durations.
These data were used because melatonin assays for these
three corneal irradiance conditions were performed as a
single batch. Post hoc 2-tailed t-tests were performed to
v e r i f yi ft h ed i f f e r e n c ev a l u e sw e r er e l i a b l yd i f f e r e n tt h a n
zero. The melatonin concentration differences between
dark and 2 μW/cm
2 were only significantly different than
zero at the 90-minute exposure duration (p = 0.05),
although the differences at the 60-minute exposure dura-
tion were almost statistically reliable (p = 0.09). The mel-
atonin concentration differences between dark and 0.7
μW/cm
2 were not significantly different than zero at any
exposure duration, indicating that 0.7 μW/cm
2 of 470
nm is very close to or at threshold for nocturnal melato-
nin suppression for exposure durations up to and includ-
ing 90 minutes (Figure 2).
Discussion
The present results investigated the impact of 90-minute
exposures from six corneal irradiances (0.7 to 72 μW/cm
2)
of 470-nm (blue) light on acute nocturnal melatonin
Figure 1 Melatonin suppression for saliva and plasma samples.
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exposure increased, melatonin suppression increased. The
present data also showed that statistically significant mela-
tonin suppression was observed after 90-minute exposure
to 2 μW/cm
2, suggesting that the threshold for acute sup-
pression by a 470-nm light is between 0.7 μW/cm
2 and
2 μW/cm
2 for this population.
Sleep disorders are common and a serious problem for
millions of older adults [24-26]. Family members, friends,
and health care workers who provide care to these indivi-
duals are also severely impacted by sleep disorders. Phar-
maceuticals are commonly used to treat sleep problems
with mixed success and at a fairly high cost. Light
therapy to correct circadian disruption may be a practi-
cal, inexpensive, and an effective treatment alternative for
older adults with sleep disorders. The present data,
together with a model of human circadian phototrans-
duction [17], enables researchers to make refined quanti-
tative predictions of light doses and clinicians to more
precisely prescribe light doses to treat circadian sleep dis-
orders in older adults.
Administering light through a personal device does not
require the person to be seated in front of a light box for
a long period of time. Individuals can wear the device
while performing routine tasks in the home. As shown
here, although no formal collection protocol was used,
Table 3 Probabilities of a Type 1 error using one sample Student’s t-test
Corneal irradiance (μW/cm
2)
Sample type Exposure duration
(min)
0.7 2 6 11 20 72
saliva 5 0.210 0.523 0.634 0.955 0.303 0.442
plasma 10 0.504 0.744 0.266 0.630 0.226 0.306
saliva 15 0.896 0.688 0.386 0.273 0.0520 0.0950
plasma 20 0.455 0.0768 0.00292 0.00048* 0.0259 0.0030
saliva 25 0.231 0.504 0.00666 0.0725 0.0008* 0.0033
plasma 30 0.533 0.414 0.133 0.0134 0.0353 0.0075
saliva 45 0.935 0.284 0.0308 0.00262 0.0021 0.0039
plasma 60 0.280 0.0078 0.00232 0.00021* 0.0004* 0.0000*
saliva 75 0.329 0.0110 0.0009 0.0011 0.0009 0.0004*
plasma 90 0.0246 0.0042 0.0009 0.0109 0.0000* 0.0000*
*- statistically different than zero suppression using the Bonferroni correction for multiple t-tests.
Figure 2 Estimation of threshold dose at different exposure durations using the difference between melatonin concentrations in the
dark and at 0.7 μW/cm
2 as well as the difference between melatonin concentrations in the dark and at 2 μW/cm
2. The asterisk indicates
a statistically reliable difference at p = 0.05.
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experiment revealed that they could comfortably watch a
movie in a darkened room while receiving their light
dose. As a result of tuning the temporal-spatial-spectral-
absolute characteristics of light to the human circadian
system, it is possible to prescribe comfortable and effec-
tive doses of light to reliably stimulate the circadian
system. This tuning reduces glare and discomfort asso-
ciated with bright white light and should thereby increase
light treatment compliance. Simple control technologies,
yet to be developed, would ensure that the light delivery
is provided at the right time and for the shortest duration
to promote circadian entrainment. The personal light
treatment device is inherently inexpensive to fabricate,
calibrate, and obviates replacing or retrofitting existing
light fixtures to deliver an effective dose of light. This is
especially important for many assisted living facilities or
nursing homes with low budgets.
In summary, the present study was able to quantify the
efficacy of a personal light treatment device for stimulating
the circadian systems of older adults without risk of retinal
damage [23]. In fact, the radiances utilized in the study
were well below levels that pose a blue-light hazard risk
[23]. Although the present data were collected in the mid-
dle of the night, this device should be used to deliver light
treatment during the daytime or during the early evening
hours. Additional studies are recommended to investigate
the ability of short-wavelength (blue) light applied during
the morning or evening hours to phase shift or to entrain
the circadian systems of older adults suffering from circa-
dian sleep disorders. Additional studies are also recom-
mended to investigate the impact of blue-light treatment
for subjective daytime sleepiness and nighttime sleep qual-
ity as well as for wake and sleep electroencephalogram.
Notwithstanding these important limitations of the pre-
sent study, the primary envisioned benefit of a personal
light treatment device is that clinicians can begin to pre-
scribe a precise dose of short-wavelength (blue) light for
older adults to reliably stimulate their circadian systems
[27]. Once a dose is determined, its brightness would be
the lowest possible because the spectrum is tuned to maxi-
mum circadian effectiveness. This also has the benefit of
limiting wasted heat from the LED, both improving energy
efficiency and minimizing tactile discomfort. A low-bright-
ness, battery-operated device that is safe, comfortable, and
portable can provide older adults with an effective light
dose while they perform their daily activities, eliminating
the need to sit in front of a light box.
Two further limitations of t h ep r e s e n ts t u d ya r et h a t
user acceptance was not formally evaluated and the
effectiveness of blue light exposures was not tested in
older adults who exhibit health problems. Although the
efficacy of blue-light treatment for improving sleep effi-
ciency in older adults, including those with AD, has
been demonstrated in earlier studies [27,28], there are
no empirical data to directly support acceptance, com-
pliance, or efficacy for treatment of sleep disorders in
larger clinical trials using older adults who are not as
healthy as those who participated in the present study.
Further, the device used in the present study is not yet a
commercial product so customer feedback in other
areas, like cost, was not obtained. Still, the device seems
quite promising for formal tests of user acceptance.
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